Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer
2025-10-01
|
| Schriftenreihe: | Discover Oncology |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1007/s12672-025-03569-x |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|